

CONTENTS

Introduction	v
Contributors	xiii

I PERSPECTIVE ON THE CLINICAL DISEASE

1 Management of Primary Malignant Melanoma	3
<i>Philip L. Bailin, Jon S. Meine, and Christine Pobleto-Lopez</i>	
2 A Pathologist's Perspective on Prognostic Features of Malignant Melanoma	39
<i>Ralph J. Tuthill</i>	
3 Clinical Prognostic Factors and Staging	73
<i>Hamed Daw and Thomas Olencki</i>	

II BIOLOGICAL AND TARGETED THERAPEUTICS

4 Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression	95
<i>Peter A. Cohen, Suyu Shu, and James H. Finke</i>	
5 Immunotherapy of Advanced Melanoma Directed at Specific Antigens	141
<i>Stanley P. L. Leong and Suyu Shu</i>	
6 Melanoma Antigens: Vaccines and Monoclonal Antibodies	157
<i>Paul B. Chapman and Jedd D. Wolchok</i>	
7 Interleukin-2	183
<i>James W. Mier and Michael B. Atkins</i>	
8 Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma	221
<i>Ronald M. Bukowski and Charles Tannenbaum</i>	
9 Interferons: Preclinical and Clinical Studies in Melanoma	235
<i>Ernest C. Borden</i>	
10 Biochemotherapy of Melanoma	259
<i>Lawrence E. Flaherty and Philip Agop Philip</i>	

11	Signal Transduction Abnormalities as Therapeutic Targets	287
	<i>Ruth Halaban and Maria C. von Willebrand</i>	
12	Tumor Angiogenesis	325
	<i>Bela Anand-Apte and Paul L. Fox</i>	
13	Antiangiogenic Therapy for Melanoma	361
	<i>Vann P. Parker</i>	
	Index	379



<http://www.springer.com/978-0-89603-876-9>

Melanoma

Biologically Targeted Therapeutics

Borden, E.C. (Ed.)

2002, XVI, 388 p., Hardcover

ISBN: 978-0-89603-876-9

A product of Humana Press